Table 2. Pharmacological antiarrhythmic treatment pre- and post-ablation.

	pre-ablation			post-ablation
	Total	PAF	non-PAF	Total	PAF	non-PAF
Patients, n	118	73	45	118	73	45
Class Ia
cibenzoline	13 (11.0)	10 (13.7)	3 (6.7)	2 (1.7)	1 (1.4)	1 (2.2)
disopyramide	4 (3.4)	4 (5.5)	0 (0.0)	1 (0.9)	1 (1.4)	0 (0.0)
pirmenol	1 (0.9)	1 (1.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Class Ib
aprindine	2 (1.7)	1 (1.4)	1 (2.2)	2 (1.7)	1 (1.4)	1 (2.2)
Class Ic
pilsicainide	18 (15.3)	16 (21.9)	2 (4.4)	5 (4.2)	5 (6.8)	0 (0.0)
flecainide	8 (6.8)	5 (6.8)	3 (6.7)	8 (6.8)	6 (8.2)	2 (4.4)
propafenone	1 (0.9)	1 (1.4)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Class III
amiodarone	2 (1.7)	1 (1.4)	1 (2.2)	1 (0.9)	1 (1.4)	0 (0.0)
sotalol	0 (0.0)	0 (0.0)	0 (0.0)	2 (1.7)	2 (2.7)	0 (0.0)
β blocker
bisoprolol	31 (26.3)	16 (21.9)	15 (33.3)	16 (13.6)	10 (13.7)	6 (13.3)
carvedilol	14 (11.9)	10 (13.7)	4 (8.9)	5 (4.2)	4 (5.5)	1 (2.2)
atenolol	6 (5.1)	3 (4.1)	3 (6.7)	2 (1.7)	0 (0.0)	2 (4.4)
Calcium channel blocker
bepridil	25 (21.2)	11 (15.1)	14 (31.1)	13 (11.0)	7 (9.6)	6 (13.3)
verapamil	4 (3.4)	3 (4.1)	1 (2.2)	1 (0.9)	0 (0.0)	1 (2.2)
digoxin	6 (5.1)	3 (4.1)	3 (6.7)	0 (0.0)	0 (0.0)	0 (0.0)

Data are n (%). non-PAF, non-paroxysmal atrial fibrillation; PAF, paroxysmal atrial fibrillation